Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

Related Articles by Review for PubMed (Select 16537662)

1.

Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators.

N Engl J Med. 2006 Apr 20;354(16):1685-97. Epub 2006 Mar 14.

2.
3.

Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.

Hoy SM, Keating GM.

Am J Cardiovasc Drugs. 2010;10(5):335-42. doi: 10.2165/11206300-000000000-00000. Review.

PMID:
20860416
4.
5.

Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.

Plosker GL, Keam SJ.

Pharmacoeconomics. 2006;24(12):1249-72. Review.

PMID:
17129078
6.

Should the results of TROPHY affect the JNC 7 definition of prehypertension?

Julius S.

Curr Hypertens Rep. 2007 Jun;9(3):202-5. Review.

PMID:
17519125
7.

Candesartan cilexetil: an angiotensin II receptor blocker.

Stoukides CA, McVoy HJ, Kaul AF.

Ann Pharmacother. 1999 Dec;33(12):1287-98. Review.

PMID:
10630830
8.

Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.

Mugellini A, Nieswandt V.

Expert Opin Pharmacother. 2012 Dec;13(18):2699-709. doi: 10.1517/14656566.2012.745511. Epub 2012 Nov 21. Review.

PMID:
23170938
9.

A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.

Zhenfeng Zheng, Huilan Shi, Junya Jia, Dong Li, Shan Lin.

J Renin Angiotensin Aldosterone Syst. 2011 Sep;12(3):365-74. doi: 10.1177/1470320310391503. Epub 2011 Mar 18. Review.

PMID:
21421652
10.

Treatment options for prehypertension.

Nesbitt SD.

Curr Opin Nephrol Hypertens. 2007 May;16(3):250-5. Review.

PMID:
17420669
11.

[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].

Sidorenko BA, Preobrazhenskiń≠ DV, Soplevenko AV, Ivanova NA, Stetsenko TM.

Kardiologiia. 2004;44(1):55-65. Review. Russian.

PMID:
15029149
12.

Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.

Bönner G, Fuchs W.

Curr Med Res Opin. 2005 Jun;21(6):935-40. Review.

PMID:
15969893
13.

An overview of candesartan in clinical practice.

Khawaja Z, Wilcox CS.

Expert Rev Cardiovasc Ther. 2011 Aug;9(8):975-82. doi: 10.1586/erc.11.90. Review.

14.

Candesartan in the treatment of hypertension: what have we learnt in the last decade?

Barrios V, Escobar C.

Expert Opin Drug Saf. 2011 Nov;10(6):957-68. doi: 10.1517/14740338.2011.608064. Epub 2011 Aug 17. Review.

PMID:
21848481
15.

Candesartan: widening indications for this angiotensin II receptor blocker?

Mendis B, Page SR.

Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. Review.

PMID:
19563275
16.

Cardiovascular outcome of an angiotensin II receptor blocker, candesartan, in Japan.

Suzuki H, Araki R.

Drugs Today (Barc). 2010 Jun;46(6):427-31. doi: 10.1358/dot.2010.46.6.1487367. Review.

PMID:
20571611
17.

Candesartan for the treatment of hypertension and heart failure.

Ostergren J.

Expert Opin Pharmacother. 2004 Jul;5(7):1589-97. Review.

PMID:
15212609
18.

Prehypertension: a possible target for antihypertensive medication.

Nesbitt SD, Julius S.

Curr Hypertens Rep. 2000 Aug;2(4):356-61. Review.

PMID:
10981170
19.
20.

Candesartan: from left ventricular hypertrophy to heart failure, a global approach.

Barrios V, Escobar C, Calderon A.

Expert Rev Cardiovasc Ther. 2007 Sep;5(5):825-34. Review. Erratum in: Expert Rev Cardiovasc Ther. 2007 Nov;5(6):1171.

PMID:
17867913
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk